MetaSight Diagnostics
Revolutionizing Liquid Biopsy
Company Overview
Snapshot
Founded in April 2020 by Tomer Shlomi, MetaSight Diagnostics operates with 11–50 employees. The company raised $8M across two funding rounds from four investors. In February 2026, MetaSight Diagnostics was acquired by Guardant Health.
Business overview
MetaSight Diagnostics develops and deploys accurate, affordable, and accessible diagnostics for diverse diseases through a single blood test, applicable for population-scale screening. Its core technology leverages a proprietary unbiased metabolomics, lipidomics, and proteomics platform to generate the world’s largest clinico multi-OMICS database. The company operates in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology, focusing on Test Diagnostics & Screening.
Strategic signal
In February 2026, MetaSight Diagnostics was acquired by Guardant Health for $59 million, with an option for an additional $90 million. This acquisition highlights the strategic value of MetaSight's liquid biopsy technology and its potential to enhance Guardant Health's diagnostic capabilities, signaling strong market demand for advanced, accessible diagnostic solutions.
Log in to access full profile ›Company Intelligence Q&A
- What was the most significant recent corporate development for MetaSight Diagnostics?
- In February 2026, MetaSight Diagnostics was acquired by Guardant Health for $59 million, with an option for an additional $90 million. This acquisition will transform MetaSight's development center in Rehovot into Guardant Health's Israeli site.
- When did MetaSight Diagnostics raise its Series A funding round?
- In November 2024, MetaSight Diagnostics raised an $8M Series A funding round from investors including.
- Who founded MetaSight Diagnostics and when?
- MetaSight Diagnostics was founded in April 2020 by Tomer Shlomi.
- What is MetaSight Diagnostics' primary focus in the healthcare sector?
- MetaSight Diagnostics focuses on developing and deploying accurate, affordable, and accessible diagnostics for various diseases using a single blood test, leveraging its proprietary multi-OMICS database for population-scale screening.